Overview

Dextenza With ILUX for Treatment of MGD

Status:
Enrolling by invitation

Trial end date:
2021-05-30

Target enrollment:

Participant gender:

Summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing iLUX MGD Treatment System.

Phase:

Phase 4

Details

Lead Sponsor:

Warrenville Eyecare

Treatments:

Dexamethasone
Prednisone